<DOC>
	<DOC>NCT00585416</DOC>
	<brief_summary>The purpose of this research is to determine the effectiveness of CGC-11047 in subjects with metastatic hormone refractory prostate cancer as measured by changes in PSA.</brief_summary>
	<brief_title>Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Metastatic hormone refractory prostate cancer. Eastern Cooperative Oncology Group (ECOG) Performance status of 01. testosterone &lt;50ng/dL. Patients must continue primary androgen deprivation with an LHRH analogue if they have not undergone orchiectomy. Progressive disease after androgen deprivation. Patients whose clinical condition would make chemotherapy clearly indicated. Patients who have received systemic chemotherapy for the treatment of metastatic disease. Peripheral neuropathy &gt; Grade 1 Prior antiangiogenic therapy, including thalidomide. Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure or radiation within 4 weeks prior to study entry. Patients who have received radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment. Patients with known brain metastases or history of brain metastases. History of stroke within 6 months of treatment or other significant neurological limitations. Patients who have received more than 2 prior investigational treatments. Uncontrolled intercurrent illness Patients with a history of a myocardial infarction within the prior 6 months or, hospitalizations for decompensated congestive heart failure within the prior 6 months, or history of significant / symptomatic cardiac arrhythmias</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Hormone Refractory</keyword>
	<keyword>Metastatic</keyword>
</DOC>